PEG-coated irinotecan cationic liposomes improve the therapeutic efficacy of breast cancer in animals

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 24, 2013, Pages 3347-3361

  Zhang, L ^a   Cao, De Ying ^a   Wang, J ^a   Xiang, B ^a   Dun, J N ^a   Fang, Y ^a   Xue, G Q ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; HPLC; PEG coated irinotecan cationic liposomes; Pharmacokinetics; Tissue distribution

Indexed keywords

IRINOTECAN; LIPOSOME; MACROGOL 2000;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER MORPHOLOGY; CIRCULATION TIME; CONTROLLED STUDY; CYTOTOXICITY; DRUG COATING; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SCREENING; DRUG UPTAKE; FEMALE; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; PARTICLE SIZE; ZETA POTENTIAL;

ANIMALS; BONE MARROW; BREAST NEOPLASMS; CAMPTOTHECIN; CATIONS; CELL LINE, TUMOR; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; LIPIDS; LIPOSOMES; MICE; MICE, INBRED BALB C; MICE, NUDE; PARTICLE SIZE; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; SURFACE PROPERTIES; TISSUE DISTRIBUTION; TOPOISOMERASE I INHIBITORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84891760255     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. BURNS MB, LACKEY L, CARPENTER MA, RATHORE A, LAND AM, LEONARD B, REFSLAND EW, KOTANDENIYA D, TRETYAKOVA N, NIKAS JB, YEE D, TEMIZ NA, DONOHUE DE, MCDOUGLE RM, BROWN WL, LAW EK, HARRIS RS. APOBEC3B is an enzymatic source of mutation in breast cancer. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 2013; 494: 366-370.
2. MONTAGNER M, ENZO E, FORCATO M, ZANCONATO F, PARENTI A, RAMPAZZO E, BASSO G, LEO G, ROSATO A, BICCIATO S, CORDENONSI M, PICCOLO S. SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. Nature 2012; 487: 380-384.
3. JEMAL A, BRAY F, CENTER MM, FERLAY J, WARD E, FORMAN D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
4. REXER BN, ARTEAGA CL. Optimal targeting of HER2- PI3K signaling in breast cancer: mechanistic insights and clinical implications. Cancer Res 2013; 73: 3817-3820.
5. HEINZEL A, MÜLLER D, LANGEN KJ, BLAUM M, VERBURG FA, MOTTAGHY FM, GALLDIKS N. The use of O-(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: a cost-effectiveness analysis. J Nucl Med 2013; 54: 1217-1222.
6. TAKANO M, GOTO T, HIRATA J, FURUYA K, HORIE K, TAKAHASHI M, YOKOTA H, KINO N, KUDOH K, KIKUCHI Y. UGT1A1 genotype-specific phase I and pharmacokinetic study for combination chemotherapy with irinotecan and cisplatin: a Saitama Tumor Board study. Eur J Gynaecol Oncol 2013; 34: 120-123.
7. RACIBORSKA A, BILSKA K, DRABKO K, CHABER R, POGORZALA M, WYROBEK E, POLCZY SKA K, ROGOWSKA E, RODRIGUEZ-GALINDO C, WOZNIAK W. Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma. Pediatr Blood Cancer 2013; 60: 1621-1625.
8. JONES RP, SUTTON P, GREENSMITH RM, SANTOYO-CASTELAZO A, CARR DF, JENKINS R, ROWE C, HAMLETT J, PARK BK, TERLIZZO M, O'GRADY E, GHANEH P, FENWICK SW, MALIK HZ, POSTON GJ, KITTERINGHAM NR. Hepatic activation of irinotecan predicts tumour response in patients with colorectal liver metastases treated with DEBIRI: exploratory findings from a phase II study. Cancer Chemother Pharmacol 2013; 72: 359-368.
9. TSUBAMOTO H, KAWAGUCHI R, ITO K, SHIOZAKI T, TAKEUCHI S, ITANI Y, ARAKAWA A, TABATA T, TOYODA S. Phase II study of carboplatin and weekly irinotecan combination chemotherapy in recurrent ovarian cancer: a Kansai clinical oncology group study (KCOG0330). Anticancer Res 2013; 33: 1073-1079.
10. GIESSEN C, LAUBENDER RP, FISCHER VON WEIKERSTHAL L, SCHALHORN A, MODEST DP, STINTZING S, HAAS M, MANSMANN UR, HEINEMANN V. Early tumor shrinkage in metastatic colorectal cancer: retrospective analysis from an irinotecan-based randomized first-line trial. Cancer Sci 2013; 104: 718-724.
11. ABU LILA AS, NAWATA K, SHIMIZU T, ISHIDA T, KIWADA H. Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration. Int J Pharm 2013; 456: 235-242.
12. TYAGI N, GHOSH PC. Folate receptor mediated targeted delivery of ricin entrapped into sterically stabilized liposomes to human epidermoid carcinoma (KB) cells: effect of monensin intercalated into folate-tagged liposomes. Eur J Pharm Sci 2011; 43: 343-353.
13. ABU-LILA A, SUZUKI T, DOI Y, ISHIDA T, KIWADA H. Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model. J Control Release 2009; 134: 18-25.
14. SONOKE S, UEDA T, FUJIWARA K, SATO Y, TAKAGAKI K, HIRABAYASHI K, OHGI T, YANO J. Tumor regression in mice by delivery of Bcl-2 small interfering RNA with pegylated cationic liposomes. Cancer Res 2008; 68: 8843-8851.
15. HO EA, OSOOLY M, STRUTT D, MASIN D, YANG Y, YAN H, BALLY M. Characterization of long-circulating cationic nanoparticle formulations consisting of a two-stage PEGylation step for the delivery of siRNA in a breast cancer tumor model. J Pharm Sci 2013; 102: 227-236.
16. NIE Y, JI L, DING H, XIE L, LI L, HE B, WU Y, GU Z. Cholesterol derivatives based charged liposomes for doxorubicin delivery: preparation, in vitro and in vivo characterization. Theranostics 2012; 2: 1092-1103.
17. ABU LILA AS, OKADA T, DOI Y, ICHIHARA M, ISHIDA T, KIWADA H. Combination therapy with metronomic S-1 dosing and oxaliplatin-containing PEG-coated cationic liposomes in a murine colorectal tumor model: synergy or antagonism. Int J Pharm 2012; 426: 263-270.
18. DI DONATO L, CATALDO M, STANO P, MASSA R, RAMUNDO-ORLANDO A. Permeability changes of cationic liposomes loaded with carbonic anhydrase induced by millimeter waves radiation. Radiat Res 2012; 178: 437-446.
19. LEE SM, AHN RW, CHEN F, FOUGHT AJ, O'HALLORAN TV, CRYNS VL, NGUYEN ST. Biological evaluation of pH-responsive polymer-caged nanobins for breast cancer therapy. ACS Nano 2010; 4: 4971-4978.
20. LEE SM, LEE OS, O'HALLORAN TV, SCHATZ GC, NGUYEN ST. Triggered release of pharmacophores from [Ni(HAsO3)]-loaded polymer-caged nanobin enhances pro-apoptotic activity: a combined experimental and theoretical study. ACS Nano 2011; 5: 3961-3969.
21. HE F, DENG X, WEN B, LIU Y, SUN X, XING L, MINAMI A, HUANG Y, CHEN Q, ZANZONICO PB, LING CC, LI GC. Noninvasive molecular imaging of hypoxia in human xenografts: comparing hypoxia-induced gene expression with endogenous and exogenous hypoxia markers. Cancer Res 2008; 68: 8597-8606.
22. XU M, WANG G, XIE H, HUANG Q, WANG W, JIA Y. Pharmacokinetic comparisons of schizandrin after oral administration of schizandrin monomer, Fructus Schisandrae aqueous extract and Sheng-Mai-San to rats. J Ethnopharmacol 2008; 115: 483-488.
23. LEE HJ, PAIK WH, LEE MG. Pharmacokinetic and tissue distribution changes of adriamycin and adriamycinol after intravenous administration of adriamycin to alloxan-induced diabetes mellitus rats. Res Commun Mol Pathol Pharmacol 1995; 89: 165-178.
24. NAGARWAL RC, KANT S, SINGH PN, MAITI P, PANDIT JK. Polymeric nanoparticulate system: a potential approach for ocular drug delivery. J Control Release 2009; 136:2-13.
25. CUONG NV, HSIEH MF. Molecular targeting of liposomal nano-particles to lymphatic system. Curr Cancer Drug Targets 2011; 11: 147-155.
26. ALLEN T M, CULLIS PR. Drug Delivery Systems: Entering the Mainstream. Science 2004; 303: 1818-1822.
27. PEER D, KARP JM, HONG S, FAROKHZAD OC, MARGALIT R, LANGER R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007; 2: 751-760.
28. CUOMO F, MOSCA M, MURGIA S, AVINO P, CEGLIE A, LOPEZ F. Evidence for the role of hydrophobic forces on the interactions of nucleotide-monophosphates with cationic liposomes. J Colloid Interface Sci 2013; 410: 146-151.
29. BARICHELLO JM, KIZUKI S, TAGAMI T, SOARES LA, ISHIDA T, KIKUCHI H, KIWADA H. Agitation during lipoplex formation harmonizes the interaction of siRNA to cationic liposomes. Int J Pharm 2012; 430: 359-365.
30. BANERJEE A, ROYCHOUDHURY J, ALI N. Stearylamine-bearing cationic liposomes kill Leishmania parasites through surface exposed negatively charged phosphatidylserine. J Antimicrob Chemother 2008; 61: 103-110.
31. KONTEK R, MATLAWSKA-WASOWSKA K, KALINOWSKA-LIS U, MARCINIAK B. Genotoxic effects of irinotecan combined with the novel platinum(II) complexes in human cancer cells. Chem Biol Interact 2010; 188: 66-74.
32. BOTHUN GD, LELIS A, CHEN Y, SCULLY K, ANDERSON LE, STONER MA. Multicomponent folate-targeted magnetoliposomes: design, characterization, and cellular uptake. Nanomedicine 2011; 7: 797-805.
33. KIM JY, KIM JK, PARK JS, BYUN Y, KIM CK. The use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activator. Biomaterials 2009; 30: 5751-5756.
34. MAGER DE, MODY V, XU C, FORREST A, LESNIAK WG, NIGAVEKAR SS, KARIAPPER MT, MINC L, KHAN MK, BALOGH LP. Physiologically based pharmacokinetic model for composite nanodevices: effect of charge and size on in vivo disposition. Pharm Res 2012; 29: 2534-2542.
35. CHENG SH, LI FC, SOURIS JS, YANG CS, TSENG FG, LEE HS, CHEN CT, DONG CY, LO LW. Visualizing dynamics of sub-hepatic distribution of nanoparticles using intravital multiphoton fluorescence microscopy. ACS Nano 2012; 6: 4122-4131.